Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohnʼs disease
BE Sands(Icahn School of Medicine at Mount Sinai), B. Feagan, Simon Lichtiger(Mount Sinai Medical Center), Stephan R. Targan(Cedars-Sinai Medical Center), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Cynthia Guzzo(Janssen (Belgium)), L-L Gao(Janssen (United States)), Subrata Ghosh(University College Cork), P. Rutgeerts, WJ Sandborn(Mayo Clinic in Arizona), Blank Ma(Johnson & Johnson (United States)), S. Hanauer(University of Illinois Chicago), Gordon R. Greenberg(University of Toronto), C-F Chiou(Johnson & Johnson (United States)), W de Villiers(University of Cape Town), Remo Panaccione(University of Calgary), Jewel Johanns(Johnson & Johnson (United States)), Christopher Gasink(Janssen (United States))
Cited by 5
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k